Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumor, HER2
Conditions
Brief summary
The goal of this observational study is to learn about in describe treatment pattern and clinical outcomes in patients with HER2-overexpressed advanced solid tumors after progression of first-line standard therapy. The main questions it aims to answer are: * To evaluate the real-world safety and efficacy of Disitamab Vedotin in second-line and beyond treatment of advanced solid tumors with HER2 overexpression * To describe the treatment pattern and clinical outcomes of patients with advanced gastric cancer with HER2 overexpression in real world Settings after the failure of first-line standard therapy.
Detailed description
This is a prospective, non-interventional, multi-cohort, multi-center real-world study to evaluate the treatment pattern and clinical outcomes of patients with advanced HER2-overexpressed solid tumors after the progression of first-line standard therapy. Enrolled subjects in this study were treated according to the treatment protocol established by physicians according to clinical routine. The tests, examinations and drug use in the study were consistent with the requirements of the clinical practice. No additional tests, examinations and drugs were generated from the data collection in this study. The study included 306 patients with HER2-overexpressed advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma and other advanced solid tumors who had failed previous first-line standard therapy. HER2 overexpression was defined as IHC2+ or IHC3+ detected by immunohistochemistry (IHC) (either primary or metastatic tumor tissue).
Interventions
DRUGDisitamab Vedotin
Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
Sponsors
RemeGen Co., Ltd.
Shen Lin
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signing informed consent and agreeing to comply with study requirements; * Age ≥18 years old, gender unlimited; * ECOG physical status 0-2 points; * Patients with locally advanced or metastatic solid tumors confirmed histologically or cytologically;Cohort1-2 cohort: patients who had received at least previous first-line standard therapy (HER2 IHC3+ or IHC2+/FISH+ patients with first-line trastuzumab (or its biosimilar) combined with chemotherapy (fluorouracil and/or platinum-based chemotherapy);IHC2+/FISH- patients with first-line Immunotherapy combined with chemotherapy (fluorouracil and/or platinum-based chemotherapy) or chemotherapy alone);In Cohort3 cohort, patients received at least the standard first-line treatment clearly recommended by the guidelines. Patients with clear disease progression confirmed by the investigator or documented history. * HER2 overexpression was defined as 2+ or 3+ immunohistochemistry (both primary and metastatic tumor tissue were acceptable), and previous patient test results (confirmed by the investigator) or center test results were acceptable. * Have measurable or evaluable lesions according to RECIST1.1 criteria; * The investigator evaluated that the patients would benefit from the study treatment; * Good compliance, willing and able to follow the trial and follow-up procedures; * Have traceable patient medical records.
Exclusion criteria
* Known hypersensitivity or delayed allergic reactions to certain components of the study drug or similar drugs; * Participating in any interventional clinical trials; * The investigator assessed inappropriate inclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of grade 3 and above adverse events associated with Disitamab Vedotin treatment during the study period. | From January 2023 to January 2025 | The incidence of grade 3 and above adverse events associated with Disitamab Vedotin treatment during the study period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence, drug correlation, and severity of adverse events during the study period | From January 2023 to January 2025 | Incidence, drug correlation, and severity of adverse events during the study period |
| Overall survival (OS) | From January 2023 to January 2025 | Time from the start of administration to death from any cause |
| Progression-free survival (PFS) | From January 2023 to January 2025 | The first objective record of disease progression or death from any cause (whichever occurs first) occurred after patients were enrolled and given the drug |
| Objective response rate (ORR) | From January 2023 to January 2025 | Refers to the proportion of patients with an optimal overall response rating of CR or PR |
Countries
China
Contacts
Primary ContactLin Shen, MD
Outcome results
None listed